Insilico Explores Abu Dhabi Listing After $337 Million Hong Kong IPO and Share Rally

Abu Dhabi | EcoPulse24

Hong Kong-listed biotech company Insilico Medicine is exploring a secondary listing on the Abu Dhabi Securities Exchange (ADX), in a move that could make it the first company from outside the Gulf region to list shares on a regional Middle East exchange.

According to people familiar with the matter cited by Bloomberg, the AI-driven drug discovery company has held preliminary discussions regarding a possible listing in Abu Dhabi as early as this year.

The proposed transaction is initially being structured as a direct listing, though shareholders may later pursue additional capital raising following the listing, the report said.

The development comes only months after Insilico completed its Hong Kong initial public offering in December, where the company raised approximately $337 million. Its shares have nearly doubled since the IPO, reflecting strong investor appetite for AI-linked healthcare and biotechnology firms.

AI and Healthcare Converge in Abu Dhabi

Insilico specializes in using artificial intelligence to accelerate drug discovery and pharmaceutical development, positioning the company at the intersection of two sectors increasingly prioritized by the UAE:

• AI infrastructure

• and advanced healthcare technologies.

The company has already established ties with Abu Dhabi through partnerships announced earlier this year with state-backed entities in the emirate.

Several Abu Dhabi-based investors also reportedly participated in the company’s Hong Kong IPO.

The potential listing aligns with Abu Dhabi’s broader strategy to attract:

• AI companies,

• biotechnology firms,

• healthcare innovators,

• and deep-tech startups

as part of the UAE’s economic diversification agenda.

Regional Exchanges Seek Global Positioning

The move would also represent a significant milestone for Gulf capital markets, which have spent recent years attempting to deepen links with international exchanges and attract foreign issuers.

While regional exchanges have signed multiple cooperation agreements with global bourses, few cross-listings have materialized so far.

Hong Kong Exchanges and Saudi Tadawul signed a partnership agreement in 2023 aimed at exploring dual listings, while Dubai Financial Market later unveiled a similar cooperation framework with Switzerland’s SIX Exchange.

The possible Insilico listing comes during a relatively weak period for Middle East IPO activity amid ongoing regional tensions and softer equity issuance volumes.

By contrast, Hong Kong equity offerings have raised more than $20 billion so far this year, compared with approximately $3.2 billion during the same period in 2025, according to Bloomberg data.

EcoPulse24 Analysis

The potential Insilico listing highlights how Abu Dhabi is increasingly positioning itself beyond a traditional energy-finance hub and toward becoming a global platform for AI, healthcare and advanced technology capital markets.

The significance of the deal extends beyond the company itself.

Insilico operates in one of the most strategically important segments of the next-generation economy:
AI-powered biotechnology and drug discovery.

That places the company directly within the UAE’s broader ambitions to build long-term economic leadership around:

• artificial intelligence,

• life sciences,

• healthcare infrastructure,

• and sovereign technology ecosystems.

A successful listing would also signal growing international confidence in Gulf capital markets as destinations not only for regional state-linked companies, but also for foreign technology firms seeking strategic investor bases and geopolitical diversification.

For Abu Dhabi specifically, attracting companies tied to AI and biotechnology supports a broader effort to reposition the emirate within the global competition for:

• advanced technologies,

• healthcare innovation,

• and future industrial ecosystems.